SOX2 expression and amplification in gliomas and glioma cell lines
L Annovazzi, M Mellai, V Caldera… - Cancer genomics & …, 2011 - cgp.iiarjournals.org
Background: The transcription factor SOX2 controls gene expression during development
and has roles in both neurogenesis and gliogenesis. Materials and Methods: The current …
and has roles in both neurogenesis and gliogenesis. Materials and Methods: The current …
[HTML][HTML] Glioblastoma: microenvironment and niche concept
…, L Annovazzi, C Casalone, C Corona, M Mellai - Cancers, 2018 - mdpi.com
The niche concept was originally developed to describe the location of normal neural stem
cells (NSCs) in the subependymal layer of the sub-ventricular zone. In this paper, its …
cells (NSCs) in the subependymal layer of the sub-ventricular zone. In this paper, its …
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors
M Mellai, A Piazzi, V Caldera, O Monzeglio… - Journal of neuro …, 2011 - Springer
A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing
and for protein expression by immunohistochemistry with mIDH1 R132H antibody. Of these, …
and for protein expression by immunohistochemistry with mIDH1 R132H antibody. Of these, …
Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies
…, D Schiffer, L Annovazzi, V Caldera, M Mellai… - Journal of …, 2014 - Elsevier
The major obstacle to glioblastoma pharmacological therapy is the overcoming of the blood–brain
barrier (BBB). In literature, several strategies have been proposed to overcome the …
barrier (BBB). In literature, several strategies have been proposed to overcome the …
[HTML][HTML] Chemotherapeutic drugs: DNA damage and repair in glioblastoma
L Annovazzi, M Mellai, D Schiffer - Cancers, 2017 - mdpi.com
Despite improvements in therapeutic strategies, glioblastoma (GB) remains one of the most
lethal cancers. The presence of the blood–brain barrier, the infiltrative nature of the tumor …
lethal cancers. The presence of the blood–brain barrier, the infiltrative nature of the tumor …
Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment
…, M Lanotte, L Annovazzi, V Caldera, M Mellai… - European journal of …, 2014 - Elsevier
Paclitaxel loaded solid lipid nanoparticles (SLN) of behenic acid were prepared with the
coacervation technique. Generally, spherical shaped SLN with mean diameters in the range 300…
coacervation technique. Generally, spherical shaped SLN with mean diameters in the range 300…
WNT/β-catenin signaling pathway and downstream modulators in low-and high-grade glioma
…, P Cassoni, A Melcarne, M Mellai… - Cancer genomics & …, 2016 - cgp.iiarjournals.org
Background: Aberrant activation of the canonical Wingless-type MMTV integration site family
(WNT)/β-catenin signaling pathway is critical for gliomas. Materials and Methods: In 74 …
(WNT)/β-catenin signaling pathway is critical for gliomas. Materials and Methods: In 74 …
mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma
L Annovazzi, M Mellai, V Caldera, G Valente… - Anticancer …, 2009 - ar.iiarjournals.org
Background: The mammalian target of rapamycin (mTOR) controls cell growth through protein
synthesis regulation. It can be activated by protein kinase B (AKT) or through ribosomal …
synthesis regulation. It can be activated by protein kinase B (AKT) or through ribosomal …
[HTML][HTML] Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies
…, E Biasibetti, D Schiffer, M Mellai… - International journal of …, 2018 - mdpi.com
Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid
nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. …
nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. …
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway
…, V Caldera, I Campia, J Kopecka, M Mellai… - Neuro …, 2013 - academic.oup.com
Background Glioblastoma multiforme stem cells display a highly chemoresistant phenotype,
whose molecular basis is poorly known. We aim to clarify this issue and to investigate the …
whose molecular basis is poorly known. We aim to clarify this issue and to investigate the …